Syros Pharmaceuticals Inc (OQ:SYRS)
Business Focus: Biotechnology & Medical Research
Apr 09, 2024 07:00 am ET
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatm
Apr 02, 2024 04:30 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (RSU) award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros. T
Mar 27, 2024 07:30 am ET
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
Mar 25, 2024 07:00 am ET
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the enrollment of 190 patients has been completed in the SELECT-MDS-1 Phase 3 clinical trial evaluating tamibarotene in newly diagnosed higher-risk myelodysplasti
Mar 20, 2024 07:00 am ET
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and
Feb 27, 2024 07:00 am ET
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference. Management will also
Feb 02, 2024 08:31 am ET
Thinking about buying stock in Biofrontera, Snowflake, Syros Pharmaceuticals, Agenus, or Kopin?
NEW YORK, Feb. 2, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BFRI, SNOW, SYRS, AGEN, and KOPN.
Feb 01, 2024 08:31 am ET
Thinking about buying stock in Applied UV, Crowdstrike, Syros Pharmaceuticals, Captivision, or Polestar Automotive?
NEW YORK, Feb. 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, CRWD, SYRS, CAPT, and PSNY.
Jan 31, 2024 08:31 am ET
Thinking about buying stock in Rivian Automotive, Bitdeer Technologies, Syros Pharmaceuticals, Lucid Group, or Ayr Wellness?
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIVN, BTDR, SYRS, LCID, and AYRWF.
Jan 08, 2024 07:00 am ET
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.
Jan 02, 2024 08:31 am ET
Thinking about buying stock in NGM Biopharmaceuticals, Syros Pharmaceuticals, Mereo BioPharma, BTCS Inc, or Sentage Holdings?
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NGM, SYRS, MREO, BTCS, and SNTG.
Dec 19, 2023 07:27 am ET
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 per pre-funded warrant, which would result in total gross proceeds of approximately $45.0 million, before underwriting discounts and commi
Dec 06, 2023 07:00 am ET
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
Nov 21, 2023 07:30 am ET
Syros to Participate in Upcoming Investor Conferences
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Management will also be available for one-on-one meetings. Details are as follows:
Nov 14, 2023 07:30 am ET
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
Nov 07, 2023 07:30 am ET
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update.
Oct 02, 2023 08:45 am ET
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the frontline treatment of higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer
Sep 07, 2023 04:30 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 20,650 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 08, 2023 07:30 am ET
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update.
Aug 04, 2023 04:30 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 16,050 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 01, 2023 07:30 am ET
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its second quarter 2023 financial results and provide a corporate update.
Jul 05, 2023 04:30 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (RSU) award for 9,000 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros. This RSU was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 13, 2023 08:00 am ET
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / June 13, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference taking place Wednesday and Thursday, June 14-15, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Jun 08, 2023 07:30 am ET
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 Virtual Small-Cap Conference. Management will also be available for one-on-one meetings. Details are as follows:
Jun 01, 2023 04:30 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 29,250 shares of Syros common stock to three newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
May 25, 2023 05:05 pm ET
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced new clinical data from the Phase 1/1b clinical trial evaluating SY-5609, its highly selective and potent inhibitor of CDK7, in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumors. The data will be presented in two posters at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.
May 10, 2023 07:30 am ET
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.
May 09, 2023 07:00 am ET
Syros to Present at JMP Securities 2023 Life Sciences Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows:
May 03, 2023 07:30 am ET
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update.
May 02, 2023 07:00 am ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 17,800 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mar 02, 2023 07:30 am ET
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.
Feb 28, 2023 07:30 am ET
Syros to Participate in Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:
Feb 23, 2023 07:30 am ET
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.
Feb 09, 2023 04:05 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 12,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 26, 2023 07:00 am ET
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overex
Jan 09, 2023 07:00 am ET
Syros Announces Clinical Updates and 2023 Strategic Priorities
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.
Dec 23, 2022 04:05 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 12, 2022 07:30 am ET
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy. These findings support Syros’ ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression. The paper, titled “Targeting RARA O
Dec 10, 2022 10:00 am ET
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The data is being presented today in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in N
Dec 05, 2022 07:00 am ET
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.
Nov 22, 2022 07:30 am ET
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Management will also be available for one-on-one meetings. Details are as follows:
Nov 14, 2022 07:30 am ET
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.
Nov 07, 2022 07:30 am ET
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.
Nov 04, 2022 04:30 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 22,610 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 03, 2022 09:01 am ET
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA. The SELECT-AML-1 trial is evaluating tamibarotene, Syros’ first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute
Oct 05, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 1,260 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 21, 2022 08:31 am ET
Thinking about buying stock in RA Medical Systems, FREYR Battery, PBF Energy, Coty, or Syros Pharmaceuticals?
NEW YORK, Sept. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RMED, FREY, PBF, COTY, and SYRS.
Sep 16, 2022 04:05 pm ET
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Shares of the combined company will trade on Nasdaq under the ticker symbol “SYRS.”
Sep 15, 2022 11:25 pm ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syros Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Sept. 15, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS).
Sep 15, 2022 04:13 pm ET
Syros and Tyme Technologies Announce Stockholder Approval of Merger
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and...
Sep 15, 2022 04:01 pm ET
Syros and Tyme Technologies Announce Stockholder Approval of Merger
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the “Merger Agreement”), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME survi
Sep 13, 2022 04:01 pm ET
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.
Sep 13, 2022 10:45 am ET
Thinking about buying stock in Syros Pharmaceuticals, American Virtual Cloud Technologies, Spectrum Pharmaceuticals, Rivian Automotive, or Peloton Interactive?
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYRS, AVCT, SPPI, RIVN, and PTON.
Sep 07, 2022 07:30 am ET
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also be available for one-on-one meetings. Details are as follows:
Sep 02, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 8,200 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 09, 2022 07:30 am ET
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.
Aug 04, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 31,000 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 03, 2022 04:01 pm ET
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan drug designation for tamibarotene for the treatment of myelodysplastic syndrome (MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS-1 Phase 3 trial for RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS).
Aug 02, 2022 07:30 am ET
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 9, 2022 to report its second quarter 2022 financial results and provide a corporate update.
Jul 27, 2022 10:05 pm ET
TYME TECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME
NEW ORLEANS, July 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to Syros Pharmaceuticals, Inc. (NasdaqGS: SYRS). Under the terms of the proposed transaction, shareholders of TYME are expected to receive approximately 0.4312 shares of Syros for each share of TYME that they own, subject to adjustment based on the amount of TYME's net cash at closing and the number of TYME shares outstanding at closing. KSF is seeking t
Jul 21, 2022 09:32 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, SYRS, SIMO
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ:...
Jul 20, 2022 03:12 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds SYRS, CNVY, RADA, and SIMO Shareholders About Its Ongoing Investigations
NEW YORK, July 20, 2022 /PRNewswire/ --
Jul 13, 2022 11:27 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Resolute Forest Products Inc. (NYSE - RFP), Meridian Bioscience, Inc. (Nasdaq - VIVO), TYME Technologies (Nasda
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jul 12, 2022 01:42 pm ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, LJPC, FSI, SYRS
NEW YORK, July 12, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 11, 2022 09:47 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds SYRS, CNVY, RADA, and SIMO Shareholders About Its Ongoing Investigations
NEW YORK, July 11, 2022 /PRNewswire/ --
Jul 05, 2022 09:46 am ET
SYRS Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Syros Pharmaceuticals, Inc. is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) and TYME Technologies, Inc. is fair to Syros shareholders. Halper Sadeh encourages Syros shareholders to click here to...
Jul 05, 2022 07:00 am ET
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $60 million. The combined company will trade on Nasdaq under the ticker symbol “SYRS” and will be led by Syros’ existing management team, including Nancy Si
Jul 01, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 48,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 08, 2022 07:30 am ET
Syros to Present at JMP Securities Life Sciences Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows:
Jun 03, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
May 16, 2022 07:30 am ET
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.
May 09, 2022 07:30 am ET
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update.
Apr 29, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 136,750 shares of Syros common stock to six newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 08, 2022 01:00 pm ET
Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data from our CDK12 inhibitor program, demonstrating robust anti-tumor activity of our oral, selective CDK12 inhibitors in models of breast, lung, and ovarian cancer, including in a PARP inhibitor resistant model. The data support the advancement of a development candidate from Syros’ CDK12 inhibitor program towards clinical development. These findings were presented in an e-poster as part of the American Association for Cancer Research (AACR) Annu
Apr 01, 2022 04:01 pm ET
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 89,400 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mar 15, 2022 07:32 am ET
Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full-year ended December 31, 2021, and provided an update on recent accomplishments and upcoming events.
Mar 09, 2022 07:30 am ET
Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.
Mar 08, 2022 04:31 pm ET
Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana.
Feb 28, 2022 07:30 am ET
Syros to Participate in Upcoming Virtual Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:
Feb 02, 2022 04:01 pm ET
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS-1 Phase 3 trial for RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS).
Jan 10, 2022 07:00 am ET
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical development programs and outlined its strategic priorities and upcoming expected milestones.
Nov 16, 2021 07:30 am ET
Syros to Participate in Upcoming Investor Conferences
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.
Nov 05, 2021 07:30 am ET
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2021, and provided an update on recent accomplishments and upcoming events.
Oct 29, 2021 07:30 am ET
Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and provide a corporate update.
Oct 13, 2021 04:01 pm ET
Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Company’s recently hired Chief Financial Officer, in accordance with Mr. Haas’s employment offer letter. The grant was approved by the Company’s Board of Directors and was made as a material inducement to Mr. Haas’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.
Oct 12, 2021 08:00 am ET
Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros.
Sep 29, 2021 08:00 am ET
Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide (ATO). The trial will evaluate the pharmacokinetics (PK), safety, and tolerability of SY-2101 to confirm the optimal dose to advance into a planned Phase 3 clinical trial in newly diagnosed acute promyelocytic leukemia (APL) patients.
Sep 28, 2021 04:01 pm ET
Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Conley Chee, the Company’s recently hired Chief Commercial Officer, in accordance with Mr. Chee’s employment offer letter. The grant was approved by the Company’s Board of Directors and was made as a material inducement to Mr. Chee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.
Sep 27, 2021 08:00 am ET
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Conley Chee as the company’s first Chief Commercial Officer. Mr. Chee brings 20 years of pharmaceutical sales leadership, marketing and strategy experience in the U.S. and globally, with particular expertise in driving commercial strategy for novel medicines for the treatment of cancer.
Sep 20, 2021 11:30 am ET
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrating clinical activity at tolerable doses as a single agent across multiple tumor types. The data is being presented today in an oral presentation at the 2021 ESMO Congress.
Sep 13, 2021 07:00 am ET
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, at the ESMO Congress 2021, taking place virtually September 16-21, 2021. The oral presentation will include safety, tolerability, and initial clinical activity data for SY-5609 in patients with breast, colorectal, lung, ovarian and pancreatic cancers, as well as in patients with so
Sep 10, 2021 07:30 am ET
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company’s Board of Directors. Dr. Dunsire is a highly respected industry veteran with more than 30 years of clinical, commercial, and international management experience within the life sciences industry.
Sep 09, 2021 08:00 am ET
Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine. The randomized Phase 2 trial is enrolling RARA-positive newly diagnosed unfit patients with acute myeloid leukemia (AML).
Sep 07, 2021 08:00 am ET
Syros to Present at Upcoming Investor Conferences in September
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at two upcoming investor conferences in September. Management will also be available for one-on-one meetings.
Aug 05, 2021 07:30 am ET
Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.
Aug 05, 2021 07:15 am ET
Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has entered into a clinical supply agreement with Roche. Under the agreement, Syros will supply SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7), for a combination dosing cohort in Roche’s ongoing Phase 1/1b INTRINSIC trial, which is evaluating multiple targeted therapies or immunotherapy, including atezolizumab, as single agents or in rational specified combinations in molecularly defined subsets of colorectal ca
Jul 29, 2021 07:30 am ET
Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and provide a corporate update.
Jun 09, 2021 08:01 am ET
Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2021 Life Sciences Conference. Details are as follows:
May 19, 2021 08:31 am ET
Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it plans to host a three-part key opinion leader (KOL) webcast series on its portfolio of investigational targeted therapies in hematology. The series will consist of presentations from Syros leaders, as well as KOLs, who will review recent progress for SY-1425 in newly diagnosed higher-risk myelodysplastic syndrome (MDS) and newly diagnosed unfit acute myeloid leukemia (AML) and for SY-2101 in acute promyelocytic leukemia (APL), and discuss the unmet need an
May 06, 2021 07:31 am ET
Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2021, and provided an update on recent accomplishments and upcoming events.
Apr 29, 2021 08:01 am ET
Syros to Report First Quarter 2021 Financial Results on Thursday May 6, 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 6, 2021 to report its first quarter 2021 financial results and provide a corporate update.
Mar 04, 2021 07:30 am ET
Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full year ended December 31, 2020, and provided an update on recent accomplishments and upcoming events.
Feb 25, 2021 08:01 am ET
Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter and full year 2020 financial results and provide a corporate update.
Feb 22, 2021 04:30 pm ET
Syros to Participate in Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that members of its management team will participate in panel discussions and present a corporate overview at upcoming investor conferences. Details are as follows:
Jan 19, 2021 10:41 pm ET
Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund the development of Syros’ ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. All shares are being off
Jan 19, 2021 04:01 pm ET
Syros Announces Proposed Offering of Common Stock
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares of its common stock in an underwritten public offering. The proceeds of the offering are expected to be used to fund the development of Syros’ ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. All of the shares in the offering are to be sold by Syros. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may b
Jan 11, 2021 07:30 am ET
Syros Announces Strategic Priorities and Expected Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.
Jan 07, 2021 01:00 pm ET
CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7)
Jan 07, 2021 08:30 am ET
Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows:
Dec 08, 2020 04:39 pm ET
Syros Closes $90.5 Million Strategic Financing
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously announced private financing with a group of institutional accredited investors led by Bain Capital Life Sciences, with participation from new and existing investors, including Ally Bridge Group, Omega Funds, OrbiMed Advisors, EcoR1 Capital, and Samsara BioCapital.
Dec 05, 2020 12:31 pm ET
Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO). SY-2101 represents a strategic opportunity to leverage Syros’ expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical-stage drug candidate that has the potential to dramatically reduce the treatment burden of a standard-of-care regimen for newly diagnos
Dec 05, 2020 12:31 pm ET
Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine in two acute myeloid leukemia (AML) patient populations. The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. In a separate poster presentation on Monday, Syros will present translational data highlighting the potential of
Nov 16, 2020 08:00 am ET
Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020.
Nov 05, 2020 04:01 pm ET
Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2020, and provided an update on recent accomplishments and upcoming events.
Nov 04, 2020 10:12 am ET
Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha (RARα) agonist, at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY-1425 in combination with azacitidine from a cohort of RARA-positive patients with relapsed or refractory acute myeloid leukem
Oct 29, 2020 08:30 am ET
Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and provide a corporate update.
Oct 24, 2020 07:30 am ET
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose (MTD) for continuous daily dosing. The data are being presented
Oct 09, 2020 07:30 am ET
Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing dose escalation portion of its Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with select solid tumors. The data will be presented in a poster session at the 32nd EORTC-NCI-AACR Symposium, taking place virtually October 24-25, 2020, and will include data on safety, pharmacokinetics and pharmacodynamics.
Sep 10, 2020 08:30 am ET
Syros Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Cantor Virtual Global Healthcare Conference. Details are as follows:
Sep 09, 2020 08:31 am ET
Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S. Gail Eckhardt, M.D., to the Company’s Board of Directors. Dr. Eckhardt is a highly respected oncologist and a leader in targeted oncology drug development.
Aug 06, 2020 07:31 am ET
Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and upcoming events.
Aug 05, 2020 09:09 am ET
Syros Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as follows:
Jul 30, 2020 08:30 am ET
Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 6, 2020 to report its second quarter 2020 financial results and provide a corporate update.
Jul 07, 2020 08:00 am ET
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.
Jun 17, 2020 08:00 am ET
Syros Announces Change to Presentation Time at JMP Securities Hematology and Oncology Forum
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a change to its presentation time at the upcoming JMP Securities Hematology and Oncology Forum. Updated details are as follows:
Jun 11, 2020 08:31 am ET
Syros to Present Virtually at JMP Securities Hematology and Oncology Forum
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows:
May 29, 2020 08:01 am ET
Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data show that SY-5609 inhibits tumor growth, including inducing sustained regressions, at well-tolerated doses in colorectal cancer models, supporting the inclusion of colorectal cancer patients in Syros’ ongoing Phase 1 clinical trial. These data were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Progr
May 28, 2020 08:00 am ET
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
CAMBRIDGE, Mass., May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
May 13, 2020 05:01 pm ET
Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in models of colorectal cancer. These data will be presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) taking place May 29-31. Syros will also present on the design of its ongoing Phase 1 trial of SY-5609 at ASCO20.
May 07, 2020 07:30 am ET
Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2020 and provided an update on recent accomplishments and upcoming events.
Apr 30, 2020 08:30 am ET
Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a corporate update.
Mar 05, 2020 07:30 am ET
Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended December 31, 2019, and provided an update on recent accomplishments and upcoming events.
Feb 27, 2020 08:00 am ET
Syros to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results and provide a corporate update.
Feb 24, 2020 08:00 am ET
Syros to Present at Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences:
Feb 13, 2020 08:00 am ET
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of a $60 million senior secured loan facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare service companies.
Jan 29, 2020 08:31 am ET
Syros Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition to Discover and Develop New Medicines for Difficult-to-Treat Cancers
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data showing that inhibiting cyclin-dependent kinase 7 (CDK7) results in different transcriptional effects than inhibiting cyclin-dependent kinase 12 (CDK12), pointing to distinct therapeutic opportunities to benefit patients with difficult-to-treat cancers. Building on its leadership in gene control, Syros also described new methods for identifying essential genes and transcriptional dependencies in cancer that could serve as potential drug targe
Jan 28, 2020 08:31 am ET
Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. The trial is enrolling patients with advanced breast, colorectal, lung or ovarian cancer, or with solid tumors of any histology that harbor Rb pathway alterations.
Jan 12, 2020 09:00 am ET
Syros Announces Strategic Priorities and Expected Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.
Dec 20, 2019 08:01 am ET
Syros Announces Appointment of Mark Alles to Its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company’s Board of Directors. Mr. Alles is a recognized biopharmaceutical executive with a proven record of building successful global oncology organizations and commercializing innovative therapies over his 30-year career.
Dec 18, 2019 07:15 am ET
GBT Secures $150 Million Non-Dilutive Term Loan Financing
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered into a $150 million loan agreement with funds managed by Pharmakon Advisors LP, a leading global life sciences investment firm and manager of the BioPharma...
Dec 18, 2019 07:00 am ET
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) today announced that they have entered into a collaboration to discover, develop and commercialize novel therapies for sickle cell disease (SCD) and...
Dec 08, 2019 08:00 am ET
Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X (NFIX), using its gene control platform. The finding sheds light on how the gamma-globin gene, which leads to the production of fetal hemoglobin, is controlled and points to new potential targets for therapeutic intervention in sickle cell disease. These data will be presented in an oral presentation tomorrow at the 61st American Society of Hematology (ASH) Annual Meeting a
Nov 26, 2019 08:31 am ET
Syros to Present at Piper Jaffray 31st Annual Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference. Details are as follows:
Nov 19, 2019 07:01 am ET
Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in triple-negative breast cancer (TNBC) in a poster presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS), taking place December 10-14 in San Antonio, Texas.
Nov 12, 2019 08:00 am ET
Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2019, and provided an update on recent accomplishments and upcoming events.
Nov 06, 2019 09:01 am ET
Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel fetal hemoglobin repressor in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting taking place December 7-10 in Orlando, Florida. The finding, which is part of Syros’ broader drug discovery effort in sickle cell disease, will also be highlighted in an ASH press briefing.
Nov 05, 2019 08:30 am ET
Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update.
Oct 29, 2019 04:01 pm ET
Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today presented new preclinical data for SY-5609, its highly-selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data demonstrate that SY-5609 induces deep and sustained anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors at doses below the maximum tolerated dose (MTD). These data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Oct 24, 2019 08:31 am ET
Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newl
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that updated clinical data from its ongoing Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine, continue to demonstrate high complete response rates, rapid onset of action and a favorable tolerability profile in a genomically defined subset of newly diagnosed acute myeloid leukemia (AML) patients who are not suitable candidates for standard intensive chemotherapy. These data
Oct 17, 2019 07:00 am ET
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its portfolio of selective cyclin-dependent kinase 7 (CDK7) inhibitors. The Company has decided to prioritize the development of its highly selective and potent oral CDK7 inhibitor, SY-5609, and to discontinue further development of SY-1365, its intravenous (IV) CDK7 inhibitor. Syros expects to initiate a Phase 1 clinical trial of SY-5609 in patients with select solid tumors in the first quarter of 2020.
Aug 06, 2019 04:01 pm ET
Syros to Present at 2019 Wedbush PacGrow Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference. Details are as follows:
Aug 01, 2019 07:31 am ET
Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2019, and provided an update on recent accomplishments and upcoming events.
Jul 25, 2019 08:30 am ET
Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 1, 2019 to report its second quarter 2019 financial results and provide a corporate update.
Jun 12, 2019 08:31 am ET
Syros Announces Appointment of Alice T. Shaw to its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the development of medicines to control the expression of
genes, today announced the appointment of Alice Tsang Shaw, M.D., Ph.D.,
to the Company’s Board of Directors. Dr. Shaw is a highly respected
oncologist and recognized leader in translational medicine and the
development of targeted cancer therapies.
Jun 12, 2019 08:01 am ET
Syros to Present at JMP Securities Life Sciences Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced that its
Chief Executive Officer, Nancy Simonian, M.D., will participate in a
fireside chat at the JMP Securities Life Sciences Conference. Details
are as follows:
May 07, 2019 08:31 am ET
New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced the
online publication of a new manuscript, Discovery and
Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7,
in the American Association for Cancer Research’s (AACR) journal, Cancer
Research. SY-1365, a first-in-class selective cyclin-dependent
kinase 7 (CDK7) inhibitor, is currently being investigated in a Phase 1
clinical trial as a single agent and in combination with
stan
May 01, 2019 07:30 am ET
Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today reported financial
results for the quarter ended March 31, 2019 and provided an update on
recent accomplishments and upcoming events.
Apr 24, 2019 08:01 am ET
Syros to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that it will host a live conference
call and webcast at 8:30 a.m. ET on Wednesday, May 1, 2019 to report its
first quarter 2019 financial results and provide a corporate update.
Apr 17, 2019 08:01 am ET
Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
will host a key opinion leader (KOL) breakfast symposium focused on the
unmet need, treatment landscape and opportunities for selective
cyclin-dependent kinase 7 (CDK7) inhibition in ovarian and breast
cancers on Wednesday, April 24, 2019 from 8:30 – 10:30 a.m. ET in New
York City. Syros is currently evaluating SY-1365, a first-in-class
selective CDK7 inhibitor, in a Phase 1 clinical trial as a single agent
Apr 09, 2019 04:01 pm ET
Syros Announces Closing of Concurrent Public Offerings
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced the
closing of its previously announced concurrent underwritten public
offerings of (i) 8,667,333 shares of its common stock and accompanying
Class A warrants to purchase up to 1,951,844 shares of its common stock,
at a combined price to the public of $7.50 per common share and
accompanying Class A warrant and (ii) 666 shares of its Series A
convertible preferred stock, which are convertible into 666,000 shares
Apr 08, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Advanced Micro Devices, Syros Pharmaceuticals, La Jolla Pharmaceutical, Integer, Mesoblast, and InnerWorkings — What Drives Growth in Today's Competitive La
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Advanced Micro Devices, Inc. (NASDAQ:AMD), Syros Pharmaceuticals, Inc....
Apr 05, 2019 07:15 am ET
Syros Announces Pricing of $70 Million Concurrent Public Offerings
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
has priced its concurrent underwritten public offerings of (i) 8,667,333
shares of its common stock and accompanying Class A warrants to purchase
up to 1,951,844 shares of its common stock, at a combined price to the
public of $7.50 per common share and accompanying Class A warrant and
(ii) 666 shares of its Series A convertible preferred stock, which are
convertible into 666,000 shares of its common stock,
Apr 04, 2019 04:18 pm ET
Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
is offering to sell, subject to market and other conditions, (i) shares
of its common stock and Class A warrants to purchase common stock, and
(ii) shares of its Series A convertible preferred stock and Class A
warrants to purchase common stock, in two concurrent but separate
underwritten public offerings. The offerings are being made by means of
separate preliminary prospectus supplements and are not conti
Apr 02, 2019 04:01 pm ET
Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today presented new
preclinical data across its franchise of selective cyclin-dependent
kinase 7 (CDK7) inhibitors at the American Association for Cancer
Research (AACR) Annual Meeting in Atlanta. New data on SY-1365, a
first-in-class selective CDK7 inhibitor currently in a Phase 1 clinical
trial, suggest that RB pathway alterations are predictive of response in
preclinical models of high-grade ovarian cancer (HGOC) and support th
Mar 07, 2019 07:30 am ET
Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today reported financial
results for the fourth quarter and full year ended December 31, 2018 and
provided an update on recent accomplishments and upcoming events.
Mar 06, 2019 08:31 am ET
Syros to Participate in Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced it will
present at the following upcoming investor conferences.
Feb 28, 2019 08:30 am ET
Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
will host a live conference call and webcast at 8:30 a.m.
ET on Thursday, March 7, 2019 to report its fourth quarter and full year
2018 financial results and provide a corporate update.
Feb 27, 2019 04:31 pm ET
Syros to Present New Preclinical Data on Its Selective CDK7 Inhibitors, SY-1365 and SY-5609, at AACR Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
will present new preclinical data on SY-1365, its first-in-class
selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a
Phase 1 clinical trial focused on ovarian and breast cancers, and on
SY-5609, its selective oral CDK7 inhibitor that the company has named as
its next development candidate, at the American Association for Cancer
Research (AACR) Annual Meeting taking place March 29-April 3 in
Feb 05, 2019 08:20 am ET
Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Re
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ArcBest Corporation (NASDAQ:ARCB), International Game Technology...
Jan 06, 2019 05:00 pm ET
Syros Announces Strategic Priorities and Expected Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today outlined its
strategic priorities and expected upcoming milestones. The Company will
review these priorities in a presentation at the 37th Annual
J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 9:00
a.m. PST (12:00 p.m. EST).
Jan 03, 2019 08:01 am ET
Syros to Present at 37th Annual J.P. Morgan Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced that its
Chief Executive Officer, Nancy Simonian, M.D., will present a corporate
overview, including 2019 objectives, at the 37th Annual J.P. Morgan
Healthcare Conference. Details are as follows:
Dec 21, 2018 08:01 am ET
Syros Added to NASDAQ Biotechnology Index
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
has been selected for addition to the NASDAQ Biotechnology Index®
(Nasdaq: NBI). The addition will become effective prior to market open
on Monday, December 24th, 2018.
Dec 07, 2018 08:01 am ET
Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced new
preclinical data on SY-1365, its first-in-class selective
cyclin-dependent kinase 7 (CDK7) inhibitor, showing that it inhibits
tumor cell growth in hormone receptor-positive (HR-positive) breast
cancer cell lines that are resistant to treatment with CDK4/6 inhibitors
and that it has synergistic activity in combination with fulvestrant in
these treatment-resistant cells. These data are being presented by
Dec 02, 2018 12:01 pm ET
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced initial
clinical data from cohorts in its ongoing Phase 2 trial evaluating
SY-1425, its first-in-class selective retinoic acid receptor alpha
(RARα) agonist, in combination with azacitidine and with daratumumab in
genomically defined patients with acute myeloid leukemia (AML) and
higher-risk myelodysplastic syndrome (MDS). These data are being
presented at the 60th American Society of Hematology (ASH)
Nov 30, 2018 08:30 am ET
Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store — Emerging Consolidated Expectations, Ana
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Gartner, Inc. (NYSE:IT), CONVERGEONE HLD (NASDAQ:CVON), Syros...
Nov 20, 2018 08:01 am ET
Syros to Present at 30th Annual Piper Jaffray Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that its
Chief Executive Officer, Nancy Simonian, M.D., will participate in a
fireside chat at the 30th Annual Piper Jaffray Healthcare
Conference. Details are as follows:
Nov 15, 2018 09:30 am ET
Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that
data from the dose escalation portion of its Phase 1 trial of SY-1365,
its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor,
demonstrated proof-of-mechanism at tolerable doses in patients with
advanced solid tumors. These data, the first clinical data reported on a
selective CDK7 inhibitor, were highlighted in an oral plenary session at
the 30th EORTC-NCI-AACR Molecular Targets an
Nov 13, 2018 07:01 am ET
Syros Presents New Preclinical Combination Data on SY-1365 and First Preclinical Data from Oral CDK7 Inhibitor Program at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced
preclinical data on SY-1365, its first-in-class selective
cyclin-dependent kinase 7 (CDK7) inhibitor, showing synergistic
anti-tumor activity in combination with carboplatin, a standard-of-care
therapy, in models of ovarian cancer and providing a mechanistic
rationale for the ongoing investigation of the combination in the Phase
1 clinical trial of SY-1365. The Company also announced the first
preclinical da
Nov 09, 2018 04:01 pm ET
Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that new
preclinical data on SY-1365, its first-in-class selective
cyclin-dependent kinase 7 (CDK7) inhibitor, will be featured in a
Spotlight poster discussion session at the San Antonio Breast Cancer
Symposium taking place December 4-8 in San Antonio. The data show that
SY-1365 has dose-dependent inhibitory activity in hormone
receptor-positive breast cancer cell lines that are resistant to
treatment with
Nov 01, 2018 09:01 am ET
Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that the
Company will present initial clinical data from both combination cohorts
in its ongoing Phase 2 trial of SY-1425, its first-in-class selective
retinoic acid receptor alpha (RARα) agonist, in genomically defined
subsets of patients with acute myeloid leukemia (AML) and higher-risk
myelodysplastic syndrome (MDS) at the 60th American Society
of Hematology (ASH) Annual Meeting and Exposition taking
Nov 01, 2018 07:00 am ET
Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today reported financial
results for the quarter ended September 30, 2018 and provided an update
on recent accomplishments and upcoming events.
Oct 30, 2018 07:01 am ET
Syros to Present Clinical and Preclinical Data on SY-1365 and Earlier-Stage Pipeline at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that the
Company will present data from the dose escalation portion of its Phase
1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase
7 (CDK7) inhibitor, in advanced solid tumor patients in an oral plenary
session at the 30th EORTC-NCI-AACR Molecular Targets and
Cancer Therapeutics Symposium taking place November 13-16 in Dublin. The
presentation will include data on safety, pharmacok
Oct 25, 2018 07:30 am ET
Syros to Report Third Quarter 2018 Financial Results on Thursday, November 1, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines to control the expression of genes, today announced that it
will host a live conference call and webcast at 7:30 a.m.
ET on Thursday, November 1, 2018 to report its third quarter 2018
financial results and provide a corporate update.
Oct 23, 2018 08:50 am ET
Market Trends Toward New Normal in Syros Pharmaceuticals, Westlake Chemical Partners LP, SITO Mobile, ShotSpotter, Motorcar Parts of America, and Benefitfocus — Emerging Consolidated Expectations, Ana
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), Westlake Chemical Partners...
Sep 26, 2018 07:31 am ET
Syros to Present at 2018 Cantor Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of
medicines that control the expression of genes, today announced that its
Chief Executive Officer, Nancy Simonian, M.D., will present a corporate
overview at the 2018 Cantor Global Healthcare Conference. Details are as
follows:
Sep 06, 2018 08:01 am ET
Syros to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the development of medicines that control the expression of
genes, today announced that its Chief Executive Officer, Nancy Simonian,
M.D., will participate in a fireside chat at the Morgan Stanley 16th
Annual Global Healthcare Conference. Details are as follows:
Aug 29, 2018 07:30 am ET
Report: Developing Opportunities within Cree, ArcBest, Syros Pharmaceuticals, Aegion, Adecoagro S.A, and Nevsun Resources — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cree, Inc. (NASDAQ:CREE), ArcBest Corporation (NASDAQ:ARCB), Syros...
Aug 08, 2018 08:01 am ET
Syros to Present at 2018 Wedbush PacGrow Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the development of medicines that control the expression of
genes, today announced that its Chief Financial Officer Joseph J. Ferra
will present a corporate overview at the 2018 Wedbush PacGrow Healthcare
Conference. Details are as follows:
Aug 07, 2018 07:30 am ET
Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today reported financial results for the quarter
ended June 30, 2018 and provided an update on recent accomplishments and
upcoming events.
Jul 31, 2018 08:01 am ET
Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that it will host a live conference
call and webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to report
its second quarter 2018 financial results and provide a corporate update.
Jul 26, 2018 08:00 am ET
Investor Expectations to Drive Momentum within ShotSpotter, Kohl's, Cheniere Energy Partners LP, Palo Alto Networks, Syros Pharmaceuticals, and Ryman Hospitality Properties — Discovering Underlying Fa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ShotSpotter Inc. (NASDAQ:SSTI), Kohl's Corporation (NYSE:KSS), Cheniere...
Jul 10, 2018 08:01 am ET
Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018
Syros
Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that it will host a key opinion
leader (KOL) breakfast symposium focused on the unmet need, treatment
landscape and opportunity for new combination approaches
Jun 14, 2018 04:01 pm ET
Syros Announces Appointment of Michael W. Bonney to Its Board of Directors
Syros
Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the development of medicines to control the expression of
genes, today announced the appointment of Michael W. Bonney to the
Company’s Board of Directors. Mr. Bonney brings extensive strategic,
operational, commercial and leadership experience in the b
May 30, 2018 08:01 am ET
Syros to Present at Upcoming Investor Conferences
Syros
Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that its Chief Executive Officer
Nancy Simonian, M.D., will present a corporate overview at upcoming
investor conferences. Details are as follows:
May 21, 2018 08:20 am ET
Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group N.V, HCI Group, Tennant, and Ebix — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), J J Snack Foods Corp....
May 16, 2018 05:01 pm ET
Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting
Syros
Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that the Company will present on
the design of its Phase 1 clinical trial of SY-1365, a first-in-class
selective cyclin-dependent kinase 7 (CDK7) inhibitor,
May 10, 2018 07:30 am ET
Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros
Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today reported financial results for the quarter
ended March 31, 2018 and provided an update on recent accomplishments
and upcoming events.
May 03, 2018 08:01 am ET
Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018
Syros
Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that it will host a live conference
call and webcast at 8:30 a.m. ET on Thursday, May 10, 2018 to report its
first quarter 2018 financial results and provide
Apr 16, 2018 08:01 am ET
Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer
Syros
Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced new preclinical data showing that
SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7)
inhibitor currently in a Phase 1 trial in patients w
Mar 26, 2018 08:30 am ET
Report: Developing Opportunities within AllianceBernstein Holding, Deutsche Bank Aktiengesellschaft, Syros Pharmaceuticals, Ply Gem, Ensco plc, and Berkshire Hills — Future Expectations, Projections M
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AllianceBernstein Holding L.P. (NYSE:AB), Deutsche Bank...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.